TY - JOUR
T1 - Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers
AU - Smit, Wouter
AU - Thijsen, Steven
AU - Van Der Kieft, Robert
AU - Van Tol, Sophie
AU - Reimerink, Johan
AU - Reusken, Chantal
AU - Rümke, Lidewij
AU - Bossink, Ailko
AU - Limonard, Gijs
AU - Heron, Michiel
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of FEMS.
PY - 2022/9/11
Y1 - 2022/9/11
N2 - Effective vaccination is a key element in the exit strategy from the current severe acute respiratory syndrome - CoV coronavirus-2 (SARS-CoV-2) pandemic, and may also offer protection against severe disease from future variants of concern. Here, we prospectively monitored T-cell responses over time, using ELISpot interferon-γ(INF-y) release assays, and B-cell responses, using serological tests, after vaccination and booster with BioNTech/Pfizer mRNA (Pfizer) and Janssen vector (Janssen/Johnson & Johnson) vaccines in hospital health care workers. Vaccine recipients were divided into seropositive and seronegative individuals at baseline, in order to determine the effect of natural immunity on vaccine-induced immune kinetics. We found that convalescent individuals mounted higher spike-specific INF-y-secreting T-cell responses and B-cell-mediated IgG responses, after receiving the Janssen vaccine or the first dose of the Pfizer vaccine. IgG levels corresponded to the virus neutralization capacity as measured by VNT assay. At 8 months postvaccination, spike-specific cellular immunity waned to low levels in individuals with or without prior natural immunity, whereas waning of humoral immunity occurred predominantly in naive individuals. The booster shot effectively reinduced both cellular and humoral immune responses. To conclude, our data supports the implemented single-dose mRNA booster strategy employed in the Netherlands. Furthermore, the level of pre-existing natural immunity may be factored into determining the optimal time window between future booster vaccines.
AB - Effective vaccination is a key element in the exit strategy from the current severe acute respiratory syndrome - CoV coronavirus-2 (SARS-CoV-2) pandemic, and may also offer protection against severe disease from future variants of concern. Here, we prospectively monitored T-cell responses over time, using ELISpot interferon-γ(INF-y) release assays, and B-cell responses, using serological tests, after vaccination and booster with BioNTech/Pfizer mRNA (Pfizer) and Janssen vector (Janssen/Johnson & Johnson) vaccines in hospital health care workers. Vaccine recipients were divided into seropositive and seronegative individuals at baseline, in order to determine the effect of natural immunity on vaccine-induced immune kinetics. We found that convalescent individuals mounted higher spike-specific INF-y-secreting T-cell responses and B-cell-mediated IgG responses, after receiving the Janssen vaccine or the first dose of the Pfizer vaccine. IgG levels corresponded to the virus neutralization capacity as measured by VNT assay. At 8 months postvaccination, spike-specific cellular immunity waned to low levels in individuals with or without prior natural immunity, whereas waning of humoral immunity occurred predominantly in naive individuals. The booster shot effectively reinduced both cellular and humoral immune responses. To conclude, our data supports the implemented single-dose mRNA booster strategy employed in the Netherlands. Furthermore, the level of pre-existing natural immunity may be factored into determining the optimal time window between future booster vaccines.
UR - http://www.scopus.com/inward/record.url?scp=85139570953&partnerID=8YFLogxK
U2 - 10.1093/femspd/ftac035
DO - 10.1093/femspd/ftac035
M3 - Article
C2 - 36089571
AN - SCOPUS:85139570953
SN - 2049-632X
VL - 80
JO - Pathogens and Disease
JF - Pathogens and Disease
IS - 1
M1 - ftac035
ER -